Moffitt Presentation at SITC 2021
Friday, November 12
| Time | Type | Title | No. | Author |
| 7 a.m. to 8 p.m. | Poster | Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known | 87 | Ahmad A. Tarhini, MD, PhD, MS |
| 7 a.m. to 8 p.m. | Poster | 4-1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells | 105 |
Emiliano Roselli, PhD |
| 7 a.m. to 8 p.m. | Poster | CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity | 179 | Jonathan A. Hensel, PhD |
| 7 a.m. to 8 p.m. | Poster | Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma immunotherapy | 195 | Renata AM. Rossetti, PhD |
| 7 a.m. to 8 p.m. | Poster | Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL) | 385 | MacLean Hall, BS |
Saturday, November 13
| Time | Type | Title | No. | Author |
| 7 a.m. to 8 p.m. | Poster | An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy | 384 |
MacLean Hall, BS |
| 7 a.m. to 8 p.m. | Poster | In vivo demethylation-mediated reversal of tumor cell-intrinsic cGAS silencing improves the efficacy of STING agonist therapy | 760 | Rana Falahat, PhD |
| 12:15 p.m. | Oral | CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) | 955 | Roger Li, MD |
